CDC16

Across TCGA pan-cancer cohorts, CDC16 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDC16 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CDC16 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDC16 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where CDC16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.635	0.923	<.001	59	view →
PDAC	OS	Median	All	0.434	0.720	.002	12	view →
LUAD	DFS	Median	III,IV	0.763	0.289	.004	10	view →
UCEC	DFS	Median	All	1.000	0.936	.021	2	view →
CCRCC	DFS	Median	II,III,IV	1.000	0.542	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDC16–HNSC (DFS)

Open the HNSC breakdown →